Total medical devices industry M&A deals worth $28.2bn were announced globally in November 2022, led by Johnson & Johnson’s $16.6bn acquisition of Abiomed, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 619.6% over the previous month of $3.92bn and a rise of 283.8% when compared with the last 12-month average, which stood at $7.35bn.
Comparing M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $28.21bn. At the country level, the US topped the list in terms of deal value at $28.21bn.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of M&A deals activity in November 2022 was the US with 26 deals, followed by the Canada with five and the UK with three.
In 2022, as of November, medical devices M&A deals worth $60.99bn were announced globally, marking an increase of 24.04% year on year.
medical devices industry M&A deals in November 2022: Top deals
The top five M&A deals accounted for 99.9% of the overall value during November 2022.
The combined value of the top five medical devices M&A deals stood at $28.19bn, against the overall value of $28.2bn recorded for the month.
The top five medical devices industry M&A deals of November 2022 tracked by GlobalData were:
1) Johnson & Johnson’s $16.6bn acquisition deal with Abiomed
2) The $8.9bn acquisition of Summit Health by VillageMD
3) WerfenLife’s $2bn acquisition deal with Immucor
4) The $615m acquisition of Apollo Endosurgery by Boston Scientific
5) Myriad Genetics’s $75m acquisition deal with Gateway Genomics
